Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: Evidence from POWER

PharmacoEconomics

Volumn 28, Issue SUPPL. 1, 2010, Pages 169-181

  Hill, Andrew M ^a,b   Gebo, Kelly ^c   Hemmett, Lindsay ^d   Löthgren, Mickael ^e   Allegri, Gabriele ^f   Smets, Erik ^g  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b TIBOTEC BVBA   (Belgium)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Tibotec a division of Janssen Cilag Ltd   (United Kingdom)

^e Janssen Cilag AB   (Sweden)

^f Janssen Cilag SpA Italia   (Italy)

^g JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; BELGIUM; BUDGET; CALCULATION; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DATA ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEDEN; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG COSTS; EUROPE; HEALTH CARE COSTS; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RITONAVIR; SULFONAMIDES; UNITED STATES; YOUNG ADULT;

EID: 78650726135     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11587510-000000000-00000     Document Type: Article

References (47)

1. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIVinfected adults with antiretroviral therapy (2006). HIV Med 2006; 7: 487-503
2. US Department of Health and Human Services (DHHS), Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2008 Nov 3 [online]. Available from URL: Http://aidsinfo.nih.gov/Guide lines/Default.aspx? MenuItem=Guidelines [Accessed 2009 Dec 10]
3. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA 2006; 296: 827-43
4. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe. 2008 Oct [online]. Available from URL: Http://www.europeanaidsclinicalsociety.org/guidelines.asp [Accessed 2009 Dec 10]
5. Olsen CH, Gatell J, Ledergerber B, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19: 319-30
6. Phillips AN, Lundgren JD. The CD4 lymphocyte count and risk of clinical progression: The T cell in HIV infection and disease. Curr Opin HIV AIDS 2006; 1: 43-9
7. Taiwo BO, Li X, Palella F, et al. Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART. HIV Med 2009; 10: 657-60
8. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23: 335-42
9. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-96
10. Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22: 841-8
11. Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22: 2143-53
12. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006; 166: 1632-41
13. Clifford GM, Franceschi S. Cancer risk in HIV-infected persons: Influence of CD4(+) count. Future Oncol 2009; 5: 669-78
14. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22: 1615-24
15. Levy A, Johnston K, Annemans L, et al. The impact of disease stage on direct medical costs of HIVmanagement: A review of the international literature. PharmacoEconomics 2010; 28 Suppl. 1: 35-47
16. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Eng J Med 2001; 344: 824-31
17. Keiser P, Nassar N, Kvanli MB, et al. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J Acquir Immune Defic Syndr 2001; 27: 14-9
18. Gebo K, Fleishman J, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era [abstract 537]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-8; Denver, CO, USA
19. Chen RY, Accortt NA, Westfall AO, et al. Distribution of healthcare expenditures for HIV-infected patients. Clin Infect Dis 2006; 42: 1003-10
20. Hill A, Hemmett L, Wilson B. Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials. HIV Clin Trials 2007; 8: 303-10
21. Hill A, Gebo K. Predicting HIV care costs using CD4 counts from clinical trials. Am J Manag Care 2007; 13: 524-8
22. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49: 2314-21
23. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003; 47: 3123-9
24. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-78
25. D'Aquila RT, Schapiro JM, Brun-Vézinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11: 92-6
26. HIV cost and services utilization study (HCSUS). Fact sheet: Agency for Health Care Research and Quality, Rockville, MD, USA; [online]. Available from URL: Http://www.ahrq.gov/data/hcsus.htm [Accessed 2009 Dec 10]
27. Hill AM, Clotet B, JohnstonM, et al. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: The POWER experience. PharmacoEconomics 2010; 28 Suppl. 1: 69-81
28. Laird NM. Missing data in longitudinal studies. Stat Med 1988; 7: 305-15
29. US Department of Labor - Bureau of Labor Statistics. Consumer Price Indexes; [online]. Available from URL: Http://www.bls.gov/cpi/[Accessed 2009 Dec 10]
30. Petrou S, Dooley M, Whitaker L, et al. The economic costs of caring for people with HIV infection and AIDS in England and Wales. PharmacoEconomics 1996; 9: 332-40
31. Curtis L, Netten A. Unit costs of health and social care 2005. Personal Social Services Research Unit, University of Kent, Canterbury, UK; 2005 [online]. Available from URL: Http://www.pssru.ac.uk/pdf/uc/uc2005/uc2005.pdf [Accessed 2009 Dec 10]
32. Caekelbergh K, Moeremans K, Annemans L, et al. Cost of care for HIV/AIDS in Belgium according to disease stage [abstract P19.5/01]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, Spain
33. Ghatnekar O, Gisslén M, Hjortsberg C, et al. Medical resource use and cost of HIV-related care in the HAART-era at a university clinic in Sweden. [abstract P19.10/01]. 11th European AIDS Conference; 2007 Oct 24-27;Madrid, Spain
34. Tramarin A, Campostrini S, PostmaMJ, et al. Amulticentre study of patient survival, disability, quality of life and cost of care: Among patients with AIDS in northern Italy. PharmacoEconomics 2004; 22: 43-53
35. Centers for Disease Control and Prevention (CDC). 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults; 1992 Dec 18 [online]. Available from URL: Http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm [Accessed 2009 Dec 10]
36. Istituto Nazionale di Statistica (INS). Indici dei prezzi al consumo. Periodo di riferimento: November; 2006 [online]. Available from URL: Http://www.istat.it [Accessed 2009 Dec 10]
37. Lazzarin A, Queiroz-Telles F, Frank I, et al. TMC114 provides durable viral load suppression in treatmentexperienced patients: POWER 1 and 2 combined week 48 analysis [abstract TUAB0104]. 16th International AIDS Conference; 2006 Aug 13-18; Toronto, Canada
38. Tibotec Pharmaceuticals Ltd. Data on file, 2007
39. Moore RD, Keruly JC, Gebo KA, et al. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr 2005; 39: 195-8
40. Ledergerber B, Lundgren JD,Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 51-62
41. Pozniak A, Jayaweera D, Hoy J, et al. Efficacy of darunavir/ritonavir in treatment-experienced HIV-1-infected patients at 96 weeks in the POWER 1 and 2 trials [abstract P7.2/07]. 11th EACS Conference; 2007 Oct 24-27; Madrid, Spain
42. Drummond MF, SculpherMJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Third Edition. New York, NY, USA: Oxford University Press Inc., 2005
43. Kumar S, Williams AC, Sandy JR. How do we evaluate the economics of health care? Eur J Orthod 2006; 28: 513-9
44. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trial. Lancet 2007; 370: 49-58
45. Cozzi Lepri A, Katzenstein TL, Ullum H, et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS 1998; 12: 1639-43
46. DeJesus E, Ortiz R, Khanlou H, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment naive HIV-1 infected patients at Week 48: ARTEMIS [abstract H-718b]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago, IL, USA
47. De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, et al. Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. J Acquir Immune Defic Syndr 2008; 49: 179-82